{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:12:01Z","timestamp":1779927121840,"version":"3.53.1"},"reference-count":78,"publisher":"Oncology Nursing Society (ONS)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ONF"],"published-print":{"date-parts":[[2017,11,1]]},"DOI":"10.1188\/17.onf.e232-e240","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T08:16:00Z","timestamp":1508487360000},"page":"E232-E240","source":"Crossref","is-referenced-by-count":5,"title":["Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors"],"prefix":"10.1188","volume":"44","author":[{"given":"Jochen","family":"Hefner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Johanna","family":"Csef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Kunzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1302","published-online":{"date-parts":[[2017,11,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Al-Barrak, J., & Cheung, W.Y. (2013). Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia. Supportive Care in Cancer, 21, 2351\u20132357. https:\/\/doi.org\/10.1007\/s00520-013-1831-6","DOI":"10.1007\/s00520-013-1831-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Al-Dewik, N.I., Morsi, H.M., Samara, M.M., Ghasoub, R.S., Gnanam, C.C., Bhaskaran, S.K., . . . Yassin, M.A. (2016). Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar? Clinical Medicine Insights Oncology, 10, 95\u2013104. https:\/\/doi.org\/10.4137\/cmo.s32822","DOI":"10.4137\/CMO.S32822"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Alcorn, S.R., Balboni, M.J., Prigerson, H.G., Reynolds, A., Phelps, A.C., Wright, A.A., . . . Balboni, T.A. (2010). \u201cIf God wanted me yesterday, I wouldn\u2019t be here today\u201d: Religious and spiritual themes in patients\u2019 experiences of advanced cancer. Journal of Palliative Medicine, 13, 581\u2013588. https:\/\/doi.org\/10.1089\/jpm.2009.0343","DOI":"10.1089\/jpm.2009.0343"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Anderson, K.R., Chambers, C.R., Lam, N., Yau, P.S., Cusano, F., Savoie, M.L., & Sheikh, N. (2015). Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. Journal of Oncology Pharmacy Practice, 21, 19\u201325. https:\/\/doi.org\/10.1177\/1078155213520261","DOI":"10.1177\/1078155213520261"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Apperley, J.F. (2015). Chronic myeloid leukaemia. Lancet, 385, 1447\u20131459. https:\/\/doi.org\/10.1016\/s0140-6736(13)62120-0","DOI":"10.1016\/S0140-6736(13)62120-0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Baccarani, M., Rosti, G., de Vivo, A., Bonifazi, F., Russo, D., Martinelli, G., . . . Tura, S. (2002). A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood, 99, 1527\u20131535.","DOI":"10.1182\/blood.V99.5.1527"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Balboni, M.J., Sullivan, A., Amobi, A., Phelps, A.C., Gorman, D.P., Zollfrank, A., . . . Balboni, T.A. (2013). Why is spiritual care infrequent at the end of life? Spiritual care perceptions among patients, nurses, and physicians and the role of training. Journal of Clinical Oncology, 31, 461\u2013467. https:\/\/doi.org\/10.1200\/jco.2012.44.6443","DOI":"10.1200\/JCO.2012.44.6443"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Balboni, M.J., Sullivan, A., Enzinger, A.C., Epstein-Peterson, Z.D., Tseng, Y.D., Mitchell, C., . . . Balboni, T.A. (2014). Nurse and physician barriers to spiritual care provision at the end of life. Journal of Pain and Symptom Management, 48, 400\u2013410. https:\/\/doi.org\/10.1016\/j.jpainsymman.2013.09.020","DOI":"10.1016\/j.jpainsymman.2013.09.020"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Balboni, T.A., Vanderwerker, L.C., Block, S.D., Paulk, M.E., Lathan, C.S., Peteet, J.R., & Prigerson, H.G. (2007). Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life. Journal of Clinical Oncology, 25, 555\u2013560. https:\/\/doi.org\/10.1200\/jco.2006.07.9046","DOI":"10.1200\/JCO.2006.07.9046"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Breccia, M., Efficace, F., & Alimena, G. (2011). Imatinib treatment in chronic myelogenous leukemia: What have we learned so far? Cancer Letters, 300, 115\u2013121. https:\/\/doi.org\/10.1016\/j.canlet.2010.10.018","DOI":"10.1016\/j.canlet.2010.10.018"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Breccia, M., Efficace, F., Sica, S., Abruzzese, E., Cedrone, M., Turri, D., . . . Alimena, G. (2015). Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leukemia Research, 39, 1055\u20131059. https:\/\/doi.org\/10.1016\/j.leukres.2015.07.004","DOI":"10.1016\/j.leukres.2015.07.004"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Chen, L.C., Chen, T.C., Huang, Y.B., & Chang, C.S. (2014). Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients. International Journal of Clinical Pharmacy, 36, 120\u2013127. https:\/\/doi.org\/10.1007\/s11096-013-9867-8","DOI":"10.1007\/s11096-013-9867-8"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Cleemput, I., & Dobbels, F. (2007). Measuring patient-reported outcomes in solid organ transplant recipients: An overview of instruments developed to date. Pharmacoeconomics, 25, 269\u2013286. https:\/\/doi.org\/10.2165\/00019053-200725040-00002","DOI":"10.2165\/00019053-200725040-00002"},{"key":"14","unstructured":"Deck, R., & R\u00f6ckelein, E. (1999). Zur Erhebung soziodemographischer und sozialmedizinischer Indikatoren in den rehabilitationswissenschaftlichen Forschungsverb\u00fcnden (pp. 84\u2013102). Frankfurt, Germany: German Association for Occupational Pensions. Retrieved from http:\/\/www.deutsche-rentenversicherung.de\/cae\/servlet\/contentblob\/208248..."},{"key":"15","doi-asserted-by":"crossref","unstructured":"Deschamps, A.E., De Geest, S., Vandamme, A.M., Bobbaers, H., Peetermans, W.E., & Van Wijngaerden, E. (2008). Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care and STDs, 22, 735\u2013743. https:\/\/doi.org\/10.1089\/apc.2007.0229","DOI":"10.1089\/apc.2007.0229"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Dunkel-Schetter, C., Feinstein, L.G., Taylor, S.E., & Falke, R.L. (1992). Patterns of coping with cancer. Health Psychology, 11, 79\u201387.","DOI":"10.1037\/0278-6133.11.2.79"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Efficace, F., Baccarani, M., Rosti, G., Cottone, F., Castagnetti, F., Breccia, M., . . . Mandelli, F. (2012). Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: An observational patient-centered outcome study. British Journal of Cancer, 107, 904\u2013909. https:\/\/doi.org\/10.1038\/bjc.2012.348","DOI":"10.1038\/bjc.2012.348"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Eliasson, L., Clifford, S., Barber, N., & Marin, D. (2011). Exploring chronic myeloid leukemia patients\u2019 reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leukemia Research, 35, 626\u2013630. https:\/\/doi.org\/10.1016\/j.leukres.2010.10.017","DOI":"10.1016\/j.leukres.2010.10.017"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Faller, H., B\u00fclzebruck, H., Drings, P., & Lang, H. (1999). Coping, distress, and survival among patients with lung cancer. Archives of General Psychiatry, 56, 756\u2013762.","DOI":"10.1001\/archpsyc.56.8.756"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Faller, H., Kraus, M.R., Burth, E.M., & Zeigert, B. (1999). Emotional condition, disease processing and cognitive status in Hodgkin\u2019s disease [Article in German]. Zeitschrift f\u00fcr Medizinische Psychologie, 8, 19\u201328.","DOI":"10.3233\/ZMP-1999-8_1_03"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Faller, H., & Schmidt, M. (2004). Prognostic value of depressive coping and depression in survival of lung cancer patients. Psycho-Oncology, 13, 359\u2013363. https:\/\/doi.org\/10.1002\/pon.783","DOI":"10.1002\/pon.783"},{"key":"22","unstructured":"Foulon, V., Sch\u00f6ffski, P., & Wolter, P. (2011). Patient adherence to oral anticancer drugs: An emerging issue in modern oncology. Acta Clinica Belgica, 66(2), 85\u201396. https:\/\/doi.org\/10.2143\/acb.66.2.2062525"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini, C., Antolini, L., Mahon, F.X., Guilhot, F., Deininger, M., Fava, C., . . . Kim, D.W. (2011). Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. Journal of the National Cancer Institute, 103, 553\u2013561. https:\/\/doi.org\/10.1093\/jnci\/djr060","DOI":"10.1093\/jnci\/djr060"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Ghodraty-Jabloo, V., Alibhai, S.M.H., Breunis, H., & Puts, M.T.E. (2016). Keep your mind off negative things: Coping with long-term effects of acute myeloid leukemia (AML). Supportive Care in Cancer, 24, 2035\u20132045. https:\/\/doi.org\/10.1007\/s00520-015-3002-4","DOI":"10.1007\/s00520-015-3002-4"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Glass, T.R., De Geest, S., Hirschel, B., Battegay, M., Furrer, H., Covassini, M., . . . Bucher, H.C. (2008). Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antiviral Therapy, 13, 77\u201385.","DOI":"10.1177\/135965350801300108"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Guilhot, F., Chastang, C., Michallet, M., Guerci, A., Harousseau, J.L., Maloisel, F., . . . Tanzer, J. (1997). Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. New England Journal of Medicine, 337, 223\u2013229. https:\/\/doi.org\/10.1056\/nejm199707243370402","DOI":"10.1056\/NEJM199707243370402"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Guilhot, F., Coombs, J., Szczudlo, T., Zernovak, O., Paolantonio, M., Bender, C., . . . Shapiro, A. (2013). The patient journey in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapies: Qualitative insights using a global ethnographic approach. Patient, 6, 81\u201392. https:\/\/doi.org\/10.1007\/s40271-013-0006-3","DOI":"10.1007\/s40271-013-0006-3"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Hall, A.E., Paul, C., Bryant, J., Lynagh, M.C., Rowlings, P., Enjeti, A., & Small, H. (2016). To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Critical Reviews in Oncology\/Hematology, 97, 247\u2013262. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.08.025","DOI":"10.1016\/j.critrevonc.2015.08.025"},{"key":"29","unstructured":"Harrer, M.E., Mosheim, R., Richter, R., Walter, M.H., & Kemmler, G. (1993). Coping and life satisfaction in patients with Hodgkin\u2019s disease in remission. A contribution to the question of adaptive aspects of coping processes [Article in German]. Psychotherapie, Psychosomatik, Medizinische Psychologie, 43, 121\u2013132."},{"key":"30","doi-asserted-by":"crossref","unstructured":"Hefner, J., Csef, E.J., & Kunzmann, V. (2016). Fear of progression in outpatients with chronic myeloid leukemia on oral tyrosine kinase inhibitors. Oncology Nursing Forum, 43, 190\u2013197. https:\/\/doi.org\/10.1188\/16.ONF.190-197","DOI":"10.1188\/16.ONF.190-197"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Hochhaus, A. (2011). Educational session: Managing chronic myeloid leukemia as a chronic disease. Hematology, 2011, 128\u2013135. https:\/\/doi.org\/10.1182\/asheducation-2011.1.128","DOI":"10.1182\/asheducation-2011.1.128"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Huang, W.C., Chen, C.Y., Lin, S.J., & Chang, C.S. (2016). Medication adherence to oral anticancer drugs: Systematic review. Expert Review of Anticancer Therapy, 16, 423\u2013432. https:\/\/doi.org\/10.1586\/14737140.2016.1159515","DOI":"10.1586\/14737140.2016.1159515"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Jabbour, E., & Kantarjian, H. (2014). Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. American Journal of Hematology, 89, 547\u2013556. https:\/\/doi.org\/10.1002\/ajh.23691","DOI":"10.1002\/ajh.23691"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Jabbour, E.J., Kantarjian, H., Eliasson, L., Cornelison, A.M., & Marin, D. (2012). Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. American Journal of Hematology, 87, 687\u2013691. https:\/\/doi.org\/10.1002\/ajh.23180","DOI":"10.1002\/ajh.23180"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Johnson, L.A. (2015). Factors influencing oral adherence: Qualitative metasummary and triangulation with quantitative evidence. Clinical Journal of Oncology Nursing, 19(Suppl.), S6\u2013S30. https:\/\/doi.org\/10.1188\/15.S1.CJON.6-30","DOI":"10.1188\/15.S1.CJON.6-30"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O\u2019Brien, S., Wassmann, B., . . . Ottmann, O.G. (2006). Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. New England Journal of Medicine, 354, 2542\u20132551. https:\/\/doi.org\/10.1056\/NEJMoa055104","DOI":"10.1056\/NEJMoa055104"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Klein, M., Geschwindner, H., & Spichiger, E. (2013). Living with a multitude of medicaments: Experiences of patients with cancer [Article in German]. Pflege, 26, 97\u2013108. https:\/\/doi.org\/10.1024\/1012-5302\/a000274","DOI":"10.1024\/1012-5302\/a000274"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Koenigsmann, M., Koehler, K., Regner, A., Franke, A., & Frommer, J. (2006). Facing mortality: A qualitative in-depth interview study on illness perception, lay theories and coping strategies of adult patients with acute leukemia 1 week after diagnosis. Leukemia Research, 30, 1127\u20131134. https:\/\/doi.org\/10.1016\/j.leukres.2005.12.016","DOI":"10.1016\/j.leukres.2005.12.016"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Kris, M.G., Benowitz, S.I., Adams, S., Diller, L., Ganz, P., Kahlenberg, M.S., . . . Petrelli, N.J. (2010). Clinical cancer advances 2010: Annual report on progress against cancer from the American Society of Clinical Oncology. Journal of Clinical Oncology, 28, 5327\u20135347. https:\/\/doi.org\/10.1200\/jco.2010.33.2742","DOI":"10.1200\/JCO.2010.33.2742"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Lam, M.S., & Cheung, N. (2016). Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia. Journal of Oncology Pharmacy Practice, 22, 741\u2013748. https:\/\/doi.org\/10.1177\/1078155215608523","DOI":"10.1177\/1078155215608523"},{"key":"41","unstructured":"Lazarus, R.S., & Folkman, S. (1984). Stress, appraisal, and coping. New York, NY: Springer."},{"key":"42","doi-asserted-by":"crossref","unstructured":"Marin, D., Bazeos, A., Mahon, F.X., Eliasson, L., Milojkovic, D., Bua, M., . . . Khorashad, J.S. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology, 28, 2381\u20132388.","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Mathes, T., Pieper, D., Antoine, S.L., & Eikermann, M. (2014). Adherence influencing factors in patients taking oral anticancer agents: A systematic review. Cancer Epidemiology, 38, 214\u2013226.","DOI":"10.1016\/j.canep.2014.03.012"},{"key":"44","doi-asserted-by":"crossref","unstructured":"McCue, D.A., Lohr, L.K., & Pick, A.M. (2014). Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy, 34, 481\u2013494.","DOI":"10.1002\/phar.1399"},{"key":"45","unstructured":"Muthny, F.A. (1989). Freiburger questionnaire for disease processing. Frankfurt, Germany: Beltz Publishing Group."},{"key":"46","unstructured":"Muthny, F.A. (1996). References for evaluation scales in quality assurance in rehabilitation\u20146. Assessment of coping processes with the Freiburg questionnaire of illness coping [Article in German]. Rehabilitation, 35(2), IX\u2013XVI."},{"key":"47","doi-asserted-by":"crossref","unstructured":"Noens, L., van Lierde, M.A., De Bock, R., Verhoef, G., Zachee, P., Berneman, Z., . . . Abraham, I. (2009). Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood, 113, 5401\u20135411. https:\/\/doi.org\/10.1182\/blood-2008-12-196543","DOI":"10.1182\/blood-2008-12-196543"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Parle, M., Jones, B., & Maguire, P. (1996). Maladaptive coping and affective disorders among cancer patients. Psychological Medicine, 26, 735\u2013744.","DOI":"10.1017\/S0033291700037752"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Partridge, A.H., Avorn, J., Wang, P.S., & Winer, E.P. (2002). Adherence to therapy with oral antineoplastic agents. Journal of the National Cancer Institute, 94, 652\u2013661.","DOI":"10.1093\/jnci\/94.9.652"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Patel, K., Foster, N.R., Farrell, A., Le-Lindqwister, N.A., Mathew, J., Costello, B., . . . Jatoi, A. (2013). Oral cancer chemotherapy adherence and adherence assessment tools: A report from North Central Cancer Group Trial N0747 and a systematic review of the literature. Journal of Cancer Education, 28, 770\u2013776. https:\/\/doi.org\/10.1007\/s13187-013-0511-z","DOI":"10.1007\/s13187-013-0511-z"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Petz, T., Diete, S., Gademann, G., & Wallesch, C.W. (2001). Coping in patients with malignant glioma in the course of radiation therapy [Article in German]. Psychotherapie, Psychosomatik, Medizinische Psychologie, 51(7), 281\u2013287. https:\/\/doi.org\/10.1055\/s-2001-15623","DOI":"10.1055\/s-2001-15623"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Phelps, A.C., Lauderdale, K.E., Alcorn, S., Dillinger, J., Balboni, M.T., Van Wert, M., . . . Balboni, T.A. (2012). Addressing spirituality within the care of patients at the end of life: Perspectives of patients with advanced cancer, oncologists, and oncology nurses. Journal of Oncology Nursing, 30, 2538\u20132544. https:\/\/doi.org\/10.1200\/jco.2011.40.3766","DOI":"10.1200\/JCO.2011.40.3766"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Pulgar, A., Garrido, S., Alcal\u00e1, A., & Reyes del Paso, G.A. (2012). Psychosocial predictors of immune response following bone marrow transplantation. Behavioral Medicine, 38, 12\u201318. https:\/\/doi.org\/10.1080\/08964289.2011.647118","DOI":"10.1080\/08964289.2011.647118"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Richardson, E.M., Sch\u00fcz, N., Sanderson, K., Scott, J.L., & Sch\u00fcz, B. (2017). Illness representations, coping, and illness outcomes in people with cancer: A systematic review and meta-analysis. Psycho-Oncology, 26, 724\u2013737. https:\/\/doi.org\/10.1002\/pon.4213","DOI":"10.1002\/pon.4213"},{"key":"55","unstructured":"Robert Koch Institute. (2016). Report on cancer in Germany 2016 [Article in German]. Retrieved from http:\/\/bit.ly\/2gJyrbc"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Ruddy, K., Mayer, E., & Partridge, A. (2009). Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clinicians, 59, 56\u201366. https:\/\/doi.org\/10.3322\/caac.20004","DOI":"10.3322\/caac.20004"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Salander, P., & Windahl, G. (1999). Does \u201cdenial\u201d really cover our everyday experiences in clinical oncology? A critical view from a psychoanalytic perspective on the use of \u201cdenial.\u201d British Journal of Medical Psychology, 72, 267\u2013279.","DOI":"10.1348\/000711299159899"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Santoleri, F., Lasala, R., Ranucci, E., La Barba, G., Di Lorenzo, R., Vetro, A., . . . Costantini, A. (2016). Medication adherence to tyrosine kinase inhibitors: 2-year analysis of medication adherence to imatinib treatment for chronic myeloid leukemia and correlation with the depth of molecular response. Acta Haematologica, 136, 45\u201351. https:\/\/doi.org\/10.1159\/000444626","DOI":"10.1159\/000444626"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Santoleri, F., Sorice, P., Lasala, R., Rizzo, R.C., & Costantini, A. (2013). Patient adherence and persistence with imatinib, nilotinib, dasatinib in clinical practice. PLOS ONE, 8(2), e56813. https:\/\/doi.org\/10.1371\/journal.pone.0056813","DOI":"10.1371\/journal.pone.0056813"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Schneider, S.M., Hess, K., & Gosselin, T. (2011). Interventions to promote adherence with oral agents. Seminars in Oncology Nursing, 27, 133\u2013141. https:\/\/doi.org\/10.1016\/j.soncn.2011.02.005","DOI":"10.1016\/j.soncn.2011.02.005"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Shah, N.P., Guilhot, F., Cortes, J.E., Schiffer, C.A., le Coutre, P., Br\u00fcmmendorf, T.H., . . . Saglio, G. (2014). Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: Follow-up of a phase 3 study. Blood, 123, 2317\u20132324. https:\/\/doi.org\/10.1182\/blood-2013-10-532341","DOI":"10.1182\/blood-2013-10-532341"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Sinclair, S., Booker, R., Fung, T., Raffin-Bouchal, S., Enns, B., Beamer, K., & Ager, N. (2016). Factors associated with post-traumatic growth, quality of life, and spiritual well-being in outpatients undergoing bone marrow transplantation: A pilot study. Oncology Nursing Forum, 43, 772\u2013780. https:\/\/doi.org\/10.1188\/16.ONF.772-780","DOI":"10.1188\/16.ONF.772-780"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Sirilla, J., & Overcash, J. (2013). Quality of life (QOL), supportive care, and spirituality in hematopoietic stem cell transplant (HSCT) patients. Supportive Care in Cancer, 21, 1137\u20131144.","DOI":"10.1007\/s00520-012-1637-y"},{"key":"64","doi-asserted-by":"crossref","unstructured":"Talpaz, M., Shah, N.P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., . . . Sawyers, C.L. (2006). Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New England Journal of Medicine, 354, 2531\u20132541. https:\/\/doi.org\/10.1056\/NEJMoa055229","DOI":"10.1056\/NEJMoa055229"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Vallurupalli, M., Lauderdale, K., Balboni, M.J., Phelps, A.C., Block, S.D., Ng, A.K., . . . Balboni, T.A. (2012). The role of spirituality and religious coping in the quality of life of patients with advanced cancer receiving palliative radiation therapy. Journal of Supportive Oncology, 10, 81\u201387. https:\/\/doi.org\/10.1016\/j.suponc.2011.09.003","DOI":"10.1016\/j.suponc.2011.09.003"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Verbrugghe, M., Duprez, V., Beeckman, D., Grypdonck, M., Quaghebeur, M., Verschueren, C., . . . Van Hecke, A. (2016). Factors influencing adherence in cancer patients taking oral tyrosine kinase inhibitors: A qualitative study. Cancer Nursing, 39, 153\u2013162. https:\/\/doi.org\/10.1097\/ncc.0000000000000250","DOI":"10.1097\/NCC.0000000000000250"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Verbrugghe, M., Timmers, L., Boons, C.C., Van Den Bemt, B.J., Hugtenburg, J.G., & Van Hecke, A. (2016). Adherence to oral anticancer agents: Healthcare providers\u2019 perceptions, beliefs and shared decision making in Belgium and the Netherlands. Acta Oncologica, 55, 437\u2013443. https:\/\/doi.org\/10.3109\/0284186x.2015.1119307","DOI":"10.3109\/0284186X.2015.1119307"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Verbrugghe, M., Verhaeghe, S., Lauwaert, K., Beeckman, D., & Van Hecke, A. (2013). Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review. Cancer Treatment Reviews, 39, 610\u2013621. https:\/\/doi.org\/10.1016\/j.ctrv.2012.12.014","DOI":"10.1016\/j.ctrv.2012.12.014"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Vermeire, E., Hearnshaw, H., Van Royen, P., & Denekens, J. (2001). Patient adherence to treatment: Three decades of research. A comprehensive review. Journal of Clinical Pharmacy and Therapeutics, 26, 331\u2013342.","DOI":"10.1046\/j.1365-2710.2001.00363.x"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Walsh, J.C., Mandalia, S., & Gazzard, B.G. (2002). Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. AIDS, 16, 269\u2013277.","DOI":"10.1097\/00002030-200201250-00017"},{"key":"71","unstructured":"Weisman, A.D. (1979). Coping with cancer. New York, NY: McGraw-Hill."},{"key":"72","doi-asserted-by":"crossref","unstructured":"Whitford, H.S., & Olver, I.N. (2012). The multidimensionality of spiritual wellbeing: Peace, meaning, and faith and their association with quality of life and coping in oncology. Psycho-Oncology, 21, 602\u2013610. https:\/\/doi.org\/10.1002\/pon.1937","DOI":"10.1002\/pon.1937"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Winn, A.N., Keating, N.L., & Dusetzina, S.B. (2016). Factors associated with tyrosine kinase inhibitor initiation and adherence among medicare beneficiaries with chronic myeloid leukemia. Journal of Clinical Oncology, 34, 4323\u20134328. https:\/\/doi.org\/10.1200\/JCO.2016.67.4184","DOI":"10.1200\/JCO.2016.67.4184"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Wu, E.Q., Johnson, S., Beaulieu, N., Arana, M., Bollu, V., Guo, A., . . . Cortes, J. (2010). Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Current Medical Research and Opinion, 26, 61\u201369. https:\/\/doi.org\/10.1185\/03007990903396469","DOI":"10.1185\/03007990903396469"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Wu, S., Chee, D., Ugalde, A., Butow, P., Seymour, J., & Schofield, P. (2015). Lack of congruence between patients\u2019 and health professionals\u2019 perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study. Palliative and Supportive Care, 13, 255\u2013263. https:\/\/doi.org\/10.1017\/s1478951513001260","DOI":"10.1017\/S1478951513001260"},{"key":"76","doi-asserted-by":"crossref","unstructured":"Yagasaki, K., Komatsu, H., & Takahashi, T. (2015). Inner conflict in patients receiving oral anticancer agents: A qualitative study. BMJ Open, 5(4), e006699. https:\/\/doi.org\/10.1136\/bmjopen-2014-006699","DOI":"10.1136\/bmjopen-2014-006699"},{"key":"77","doi-asserted-by":"crossref","unstructured":"Yood, M.U., Oliveria, S.A., Cziraky, M., Hirji, I., Hamdan, M., & Davis, C. (2012). Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Current Medical Research and Opinion, 28, 213\u2013219.","DOI":"10.1185\/03007995.2011.649849"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Zaza, C., Sellick, S.M., & Hillier, L.M. (2005). Coping with cancer: What do patients do. Journal of Psychosocial Oncology, 23, 55\u201373.","DOI":"10.1300\/J077v23n01_04"}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/onf.ons.org\/onf\/44\/6\/adherence-and-coping-strategies-outpatients-chronic-myeloid-leukemia-receiving-oral","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:51:48Z","timestamp":1763754708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/44\/6\/adherence-and-coping-strategies-outpatients-chronic-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1188\/17.onf.e232-e240","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"value":"0190-535X","type":"print"},{"value":"1538-0688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,1]]}}}